Literature DB >> 20566569

The time course of peritoneal transport parameters in peritoneal dialysis patients who develop encapsulating peritoneal sclerosis.

Denise E Sampimon1, Annemieke M Coester, Dirk G Struijk, Raymond T Krediet.   

Abstract

BACKGROUND: Encapsulating peritoneal sclerosis (EPS) is a severe complication of peritoneal dialysis (PD). The first aim was to analyse the risk of EPS in patients who had developed ultrafiltration failure (UFF). The second aim was to identify specific peritoneal transport alterations that distinguish patients with UFF from patients who will develop EPS.
METHODS: All patients of this study were treated with PD between July 1995 and December 2008 in the Academic Medical Center, Amsterdam, the Netherlands. Risk analysis: all PD patients who developed UFF after at least 2 years of PD. Peritoneal transport analysis: all patients who had PD for at least 55 months were included: 12 EPS patients, 21 patients with UFF and 26 patients with normal ultrafiltration (UF). The peritoneal function was measured yearly with a standard peritoneal permeability analysis. UFF was defined as net UF < 400 mL after a 4-h dwell with a 3.86% dialysis solution.
RESULTS: Risk analysis: Of the 48 UFF patients, 10 eventually developed EPS. Fifty percent of the patients who continued PD for more than 3 years after the establishment of UFF developed EPS. Peritoneal function analysis: No differences were present for the time courses of solute transport and fluid transport between the EPS and the UFF groups. Overall, the EPS and normal UF groups had lower values for the effective lymphatic absorption rate (ELAR) than the UFF group.
CONCLUSIONS: The risk of EPS increases with continuation of PD while UFF is present. Transport characteristics are similar between EPS patients and UFF patients without this complication. A constantly low ELAR may distinguish the EPS patients from those with UFF only.

Entities:  

Mesh:

Year:  2010        PMID: 20566569     DOI: 10.1093/ndt/gfq343

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  21 in total

Review 1.  Protecting the peritoneal membrane: factors beyond peritoneal dialysis solutions.

Authors:  Anneleen Pletinck; Raymond Vanholder; Nic Veys; Wim Van Biesen
Journal:  Nat Rev Nephrol       Date:  2012-07-10       Impact factor: 28.314

2.  Can effluent matrix metalloproteinase 2 and plasminogen activator inhibitor 1 be used as biomarkers of peritoneal membrane alterations in peritoneal dialysis patients?

Authors:  Deirisa Lopes Barreto; Annemieke M Coester; Dirk G Struijk; Raymond T Krediet
Journal:  Perit Dial Int       Date:  2013-09-01       Impact factor: 1.756

3.  TGF-β1 promotes lymphangiogenesis during peritoneal fibrosis.

Authors:  Hiroshi Kinashi; Yasuhiko Ito; Masashi Mizuno; Yasuhiro Suzuki; Takeshi Terabayashi; Fumiko Nagura; Ryohei Hattori; Yoshihisa Matsukawa; Tomohiro Mizuno; Yukihiro Noda; Hayato Nishimura; Ryosuke Nishio; Shoichi Maruyama; Enyu Imai; Seiichi Matsuo; Yoshifumi Takei
Journal:  J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 10.121

4.  Towards standardized reporting in studies of encapsulating peritoneal sclerosis.

Authors:  Mark Lambie; Niko Braun; Simon J Davies
Journal:  Perit Dial Int       Date:  2013 Sep-Oct       Impact factor: 1.756

5.  Alterations of peritoneal transport characteristics in dialysis patients with ultrafiltration failure: tissue and capillary components.

Authors:  Joanna Stachowska-Pietka; Jan Poleszczuk; Michael F Flessner; Bengt Lindholm; Jacek Waniewski
Journal:  Nephrol Dial Transplant       Date:  2019-05-01       Impact factor: 5.992

6.  The peritoneal sieving of sodium: a simple and powerful test to rule out the onset of encapsulating peritoneal sclerosis in patients undergoing peritoneal dialysis.

Authors:  Vincenzo La Milia; Selena Longhi; Elisabetta Sironi; Giuseppe Pontoriero
Journal:  J Nephrol       Date:  2016-12-24       Impact factor: 3.902

7.  Interstitial Fibrosis Restricts Osmotic Water Transport in Encapsulating Peritoneal Sclerosis.

Authors:  Johann Morelle; Amadou Sow; Nicolas Hautem; Caroline Bouzin; Ralph Crott; Olivier Devuyst; Eric Goffin
Journal:  J Am Soc Nephrol       Date:  2015-01-30       Impact factor: 10.121

Review 8.  Encapsulating peritoneal sclerosis: the state of affairs.

Authors:  Mario R Korte; Denise E Sampimon; Michiel G H Betjes; Raymond T Krediet
Journal:  Nat Rev Nephrol       Date:  2011-08-02       Impact factor: 28.314

9.  Can EPS development be avoided with early interventions? The potential role of tamoxifen--a single-center study.

Authors:  Erika De Sousa-Amorim; Gloria Del Peso; M Auxiliadora Bajo; Laura Alvarez; Marta Ossorio; Fernando Gil; Teresa Bellon; Rafael Selgas
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

10.  Dialysate cytokine levels do not predict encapsulating peritoneal sclerosis.

Authors:  Catriona Goodlad; Frederick W K Tam; Sohail Ahmad; Gurjeet Bhangal; Bernard V North; Edwina A Brown
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.